Australia markets closed

Sanofi (SNYNF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
99.250.00 (0.00%)
As of 12:50PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close99.25
Open101.46
Bid0.00 x 0
Ask0.00 x 0
Day's range99.25 - 99.25
52-week range86.12 - 110.45
Volume447
Avg. volume26,198
Market cap125.037B
Beta (5Y monthly)0.44
PE ratio (TTM)25.58
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield4.06 (4.09%)
Ex-dividend date13 May 2024
1y target estN/A
  • Yahoo Finance Video

    Novavax shares skyrocket on $1.2 billion Sanofi vaccine deal

    Novavax (NVAX) shares are skyrocketing after announcing a $1.2 billion deal with Sanofi (SNY) to commercialize a combined COVID-19 and flu shot. Yahoo Finance's Anjalee Khemlani joins The Morning Brief to report more on the story. The Novavax-Sanofi deal also includes co-commercialization of the COVID-19 vaccine currently on the market. Novavax will be entitled to an additional $200 million for any new vaccines involving its adjuvant. Sanofi will receive a minority stake of less than 5% in Novavax and will invest $70 million. Shares of Novavax jumped more than 120% following the news. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Melanie Riehl

  • Yahoo Finance Video

    Stock markets, China tariffs, Novavax and Sanofi: 3 Things

    The major stock market indexes (^DJI, ^IXIC, ^GSPC) are on the road to closing out the first full trading week of May on a high note, alongside several of its European counterparts: the FTSE 100 (^FTSE), the DAX Performance Index (^GDAXI), and the CAC 40 (^FCHI). President Biden is reportedly set to announce updates on Trump-era trade tariffs on China. Novavax (NVAX) shares are skyrocketing over 110% on news of the biotech company's plans to licensing deal with Sanofi (SNY, SAN.PA) to co-commercialize its COVID-19 vaccine For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.

  • Barrons.com

    Novavax Stock Surges 120% on $1.4 Billion Deal With Sanofi

    Novavax the pharmaceutical company that last year warned that falling sales of its Covid-19 vaccine could put it out of business, said it reached a $1.4 billion deal with French company Sanofi to commercialize its existing treatment and develop a new one. Shares spiked 120% in premarket trading to $10.02. Sanofi agreed to pay $500 million upfront and spend another $700 million when the company hits development, regulatory and launch milestones, Novavax said in a statement Friday.